BioSpace News Archive

Keystone Dental Inc. announced that it has completed the acquisition of Osteon Medical, a Melbourne, Australia-based technology company providing digital solutions for clinicians and dental laboratories leveraging proprietary software and unique hardware developments, significantly improving digital workflows.

XORTX Therapeutics Inc. is pleased to advise that further to its press release of April 6, 2021 that announced the intention of grant, the Company has now received receipt of the patent grant “EPO National Stage of PCT International Application for Compositions and Methods for Treatment and Prevention of Hyperuricemia Related Health Consequences” by the European Patent Office.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces significant enhancements to its Real Intelligence digital ecosystem and surgical robotics programs at the American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting in San Diego.

Karyopharm Therapeutics Inc. announced that in connection with the hiring of Eleonora Goldberg, Senior Vice President of Global Medical & Scientific Affairs, the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 100,000 shares of Karyopharm’s common stock to Dr. Goldberg, with a grant date of August 31, 2021.

Orthofix Announces First US Pediatric Implant of the Fitbone Limb-Lengthening System

CytoSorbents Corporation announced that topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry were presented at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) in Brussels, Belgium yesterday.

Chemomab Therapeutics, Ltd . today announced that the Company will participate in the following upcoming investor conferences in September.

Nephros, Inc. today announced the appointment of Wes Lobo to the role of Chief Commercial Officer.

Bellicum Pharmaceuticals, Inc . and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe®

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19